A clinical trial of glutathione supplementation in autism spectrum disorders

Janet K. Kern, David A. Geier, James Adams, Carolyn R. Garver, Tapan Audhya, Mark R. Geier

Research output: Contribution to journalArticle

28 Citations (Scopus)

Abstract

Background: Recent evidence shows that subjects diagnosed with an autism spectrum disorder (ASD) have significantly lower levels of glutathione than typically developing children. The purpose of this study was to examine the use of two commonly used glutathione supplements in subjects diagnosed with an ASD to determine their efficacy in increasing blood glutathione levels in subjects diagnosed with an ASD. Material/Methods: The study was an eight-week, open-label trial using oral lipoceutical glutathione (n=13) or transdermal glutathione (n=13) in children, 3-13 years of age, with a diagnosis of an ASD. Subjects underwent pre- and post-treatment lab testing to evaluate plasma reduced glutathione, oxidized glutathione, cysteine, taurine, free and total sulfate, and whole-blood glutathione levels. Results: The oral treatment group showed significant increases in plasma reduced glutathione, but not wholeblood glutathione levels following supplementation. Both the oral and transdermal treatment groups showed significant increases in plasma sulfate, cysteine, and taurine following supplementation. Conclusions: The results suggest that oral and transdermal glutathione supplementation may have some benefit in improving some of the transsulfuration metabolites. Future studies among subjects diagnosed with an ASD should further explore the pharmacokinetics of glutathione supplementation and evaluate the potential effects of glutathione supplementation upon clinical symptoms.

Original languageEnglish (US)
JournalMedical Science Monitor
Volume17
Issue number12
StatePublished - 2011

Fingerprint

Glutathione
Clinical Trials
Taurine
Sulfates
Cysteine
Autism Spectrum Disorder
Glutathione Disulfide
Therapeutics
Pharmacokinetics

Keywords

  • Autism
  • Glutathione
  • Oral
  • Transdermal
  • Transsulfuration metabolites

ASJC Scopus subject areas

  • Medicine(all)

Cite this

Kern, J. K., Geier, D. A., Adams, J., Garver, C. R., Audhya, T., & Geier, M. R. (2011). A clinical trial of glutathione supplementation in autism spectrum disorders. Medical Science Monitor, 17(12).

A clinical trial of glutathione supplementation in autism spectrum disorders. / Kern, Janet K.; Geier, David A.; Adams, James; Garver, Carolyn R.; Audhya, Tapan; Geier, Mark R.

In: Medical Science Monitor, Vol. 17, No. 12, 2011.

Research output: Contribution to journalArticle

Kern, JK, Geier, DA, Adams, J, Garver, CR, Audhya, T & Geier, MR 2011, 'A clinical trial of glutathione supplementation in autism spectrum disorders', Medical Science Monitor, vol. 17, no. 12.
Kern, Janet K. ; Geier, David A. ; Adams, James ; Garver, Carolyn R. ; Audhya, Tapan ; Geier, Mark R. / A clinical trial of glutathione supplementation in autism spectrum disorders. In: Medical Science Monitor. 2011 ; Vol. 17, No. 12.
@article{58cca7cc609847bb96ca5d3937b8394f,
title = "A clinical trial of glutathione supplementation in autism spectrum disorders",
abstract = "Background: Recent evidence shows that subjects diagnosed with an autism spectrum disorder (ASD) have significantly lower levels of glutathione than typically developing children. The purpose of this study was to examine the use of two commonly used glutathione supplements in subjects diagnosed with an ASD to determine their efficacy in increasing blood glutathione levels in subjects diagnosed with an ASD. Material/Methods: The study was an eight-week, open-label trial using oral lipoceutical glutathione (n=13) or transdermal glutathione (n=13) in children, 3-13 years of age, with a diagnosis of an ASD. Subjects underwent pre- and post-treatment lab testing to evaluate plasma reduced glutathione, oxidized glutathione, cysteine, taurine, free and total sulfate, and whole-blood glutathione levels. Results: The oral treatment group showed significant increases in plasma reduced glutathione, but not wholeblood glutathione levels following supplementation. Both the oral and transdermal treatment groups showed significant increases in plasma sulfate, cysteine, and taurine following supplementation. Conclusions: The results suggest that oral and transdermal glutathione supplementation may have some benefit in improving some of the transsulfuration metabolites. Future studies among subjects diagnosed with an ASD should further explore the pharmacokinetics of glutathione supplementation and evaluate the potential effects of glutathione supplementation upon clinical symptoms.",
keywords = "Autism, Glutathione, Oral, Transdermal, Transsulfuration metabolites",
author = "Kern, {Janet K.} and Geier, {David A.} and James Adams and Garver, {Carolyn R.} and Tapan Audhya and Geier, {Mark R.}",
year = "2011",
language = "English (US)",
volume = "17",
journal = "Medical Science Monitor",
issn = "1234-1010",
publisher = "International Scientific Literature Inc.",
number = "12",

}

TY - JOUR

T1 - A clinical trial of glutathione supplementation in autism spectrum disorders

AU - Kern, Janet K.

AU - Geier, David A.

AU - Adams, James

AU - Garver, Carolyn R.

AU - Audhya, Tapan

AU - Geier, Mark R.

PY - 2011

Y1 - 2011

N2 - Background: Recent evidence shows that subjects diagnosed with an autism spectrum disorder (ASD) have significantly lower levels of glutathione than typically developing children. The purpose of this study was to examine the use of two commonly used glutathione supplements in subjects diagnosed with an ASD to determine their efficacy in increasing blood glutathione levels in subjects diagnosed with an ASD. Material/Methods: The study was an eight-week, open-label trial using oral lipoceutical glutathione (n=13) or transdermal glutathione (n=13) in children, 3-13 years of age, with a diagnosis of an ASD. Subjects underwent pre- and post-treatment lab testing to evaluate plasma reduced glutathione, oxidized glutathione, cysteine, taurine, free and total sulfate, and whole-blood glutathione levels. Results: The oral treatment group showed significant increases in plasma reduced glutathione, but not wholeblood glutathione levels following supplementation. Both the oral and transdermal treatment groups showed significant increases in plasma sulfate, cysteine, and taurine following supplementation. Conclusions: The results suggest that oral and transdermal glutathione supplementation may have some benefit in improving some of the transsulfuration metabolites. Future studies among subjects diagnosed with an ASD should further explore the pharmacokinetics of glutathione supplementation and evaluate the potential effects of glutathione supplementation upon clinical symptoms.

AB - Background: Recent evidence shows that subjects diagnosed with an autism spectrum disorder (ASD) have significantly lower levels of glutathione than typically developing children. The purpose of this study was to examine the use of two commonly used glutathione supplements in subjects diagnosed with an ASD to determine their efficacy in increasing blood glutathione levels in subjects diagnosed with an ASD. Material/Methods: The study was an eight-week, open-label trial using oral lipoceutical glutathione (n=13) or transdermal glutathione (n=13) in children, 3-13 years of age, with a diagnosis of an ASD. Subjects underwent pre- and post-treatment lab testing to evaluate plasma reduced glutathione, oxidized glutathione, cysteine, taurine, free and total sulfate, and whole-blood glutathione levels. Results: The oral treatment group showed significant increases in plasma reduced glutathione, but not wholeblood glutathione levels following supplementation. Both the oral and transdermal treatment groups showed significant increases in plasma sulfate, cysteine, and taurine following supplementation. Conclusions: The results suggest that oral and transdermal glutathione supplementation may have some benefit in improving some of the transsulfuration metabolites. Future studies among subjects diagnosed with an ASD should further explore the pharmacokinetics of glutathione supplementation and evaluate the potential effects of glutathione supplementation upon clinical symptoms.

KW - Autism

KW - Glutathione

KW - Oral

KW - Transdermal

KW - Transsulfuration metabolites

UR - http://www.scopus.com/inward/record.url?scp=82755165773&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=82755165773&partnerID=8YFLogxK

M3 - Article

VL - 17

JO - Medical Science Monitor

JF - Medical Science Monitor

SN - 1234-1010

IS - 12

ER -